ISCK03

ISCK03 is a SCF/c-Kit and CD117-specific inhibitor. ISCK03 significantly inhibits c-Kit phosphorylation at 10 μM[1][2][3].

Product Specifications

CAS Number

[945526-43-2]

UNSPSC

12352005

Hazard Statement

H319

Target

C-Kit

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ISCK03.html

Purity

98.30

Solubility

DMSO : ≥ 38 mg/mL

Smiles

O=S(C1=CC=C(C(C)(C)C)C=C1)(NC2=CC=C(N3C=CN=C3)C=C2)=O

Molecular Formula

C19H21N3O2S

Molecular Weight

355.45

Precautions

H319

References & Citations

[1]Na YJ, et al. [4-t-butylphenyl]-N- (4-imidazol-1-yl phenyl) sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol. 2007 Sep 1;74 (5) :780-6.|[2]Hirano T, et al. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer. 2015 Apr 19;14:90. doi: 10.1186/s12943-015-0364-7.|[3]Wintzell M, et al. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther. 2012 Dec;13 (14) :1454-62.